Clinical Trials Logo

Carcinoma in Situ clinical trials

View clinical trials related to Carcinoma in Situ.

Filter by:

NCT ID: NCT04022772 Completed - Breast Carcinoma Clinical Trials

Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer

Start date: July 31, 2019
Phase: N/A
Study type: Interventional

This trial studies the effect of an electronic health (eHealth) support program called PACK Health on patient reported health outcomes in patients with breast cancer. PACK Health monitors breast cancer patients' reported side effects and experience of care when receiving chemotherapy. Participating in the PACK Health coaching program may improve quality of life, decrease hospital admissions and improve overall health.

NCT ID: NCT03834532 Completed - Clinical trials for Breast Cancer Female

Living Well After Breast Surgery

Start date: February 18, 2019
Phase: N/A
Study type: Interventional

Decision making about whether to have breast reconstruction after mastectomy can be difficult, and previous studies have found that many women are not well informed about their options. Patient decision aids can improve decision quality for a variety of health conditions. This pilot randomized study seeks to determine how a patient decision aid about breast reconstruction affects the quality of decisions about reconstruction including patient knowledge, concordance between preferences and treatment, and decisional regret.

NCT ID: NCT03808818 Completed - Malignant Neoplasm Clinical Trials

Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices

Start date: August 1, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well smoking cessation treatment plans work in tobacco-dependent cancer patients when delivered virtually as part of their cancer care in community oncology practices. Virtual information and counseling sessions may help cancer patients quit smoking.

NCT ID: NCT03775213 Completed - Clinical trials for Ductal Carcinoma in Situ

Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS)

Start date: October 12, 2021
Phase: N/A
Study type: Interventional

The purpose of this research study is to evaluate a decision support tool for patients diagnosed with ductal carcinoma in situ (DCIS).

NCT ID: NCT03721978 Completed - Cervical Dysplasia Clinical Trials

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Start date: April 9, 2019
Phase: Phase 3
Study type: Interventional

HPV-303 is a prospective, randomized, double-blind, placebo-controlled phase 3 study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRAâ„¢ 5PSP in adult women with histologically confirmed high-grade squamous intraepithelial lesions (HSIL) (cervical intraepithelial neoplasia grade 2 [CIN2] or grade 3 [CIN3]) of the cervix, associated with HPV-16 and/or HPV-18.

NCT ID: NCT03703492 Completed - Breast Cancer Clinical Trials

Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS

Start date: January 3, 2019
Phase: Phase 2
Study type: Interventional

This prospective, one-arm study which will enroll participants with biopsy-proven DCIS scheduled for diagnostic breast MRI for preoperative staging/extent of disease evaluation as part of standard of care. Eligible participants will be consented for participation in the research study which includes a directed breast PET/MRI with 18F-FES. 18F-FES uptake of the known malignancy will be measured on the PET/MRI examination using standardized uptake values (SUV) and tumor-to-normal tissue ratios.

NCT ID: NCT03697226 Completed - Cervical Cancer Clinical Trials

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.

Start date: December 21, 2018
Phase: Phase 1
Study type: Interventional

This study evaluates the use of ABI-1968, a topical cream, in the treatment of cervical precancerous lesions in females without human immunodeficiency virus (HIV) infection.

NCT ID: NCT03669952 Completed - Clinical trials for Outcome of Breast Cancer

Study of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer

Start date: January 1, 2010
Phase:
Study type: Observational [Patient Registry]

A prospective observational longitudinal study of 464 patients was performed between 2010 and 2015. Patients with invasive ductal carcinoma (IDC) and ductal carcinoma in situ associated to invasive ductal carcinoma (DCIS +IDC) were included and analyzed.

NCT ID: NCT03499795 Completed - Anal Neoplasm Clinical Trials

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

Start date: May 15, 2018
Phase: Phase 2
Study type: Interventional

This is a phase 2, open-label efficacy study of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP) in adult men and women who are human immunodeficiency virus (HIV) negative with histologically confirmed anal or anal/peri-anal high-grade squamous intraepithelial lesion (HSIL) associated with human papilloma virus (HPV)-16 and/or HPV-18. Approximately 24 participants will receive at least 3 doses of VGX-3100.

NCT ID: NCT03436251 Completed - Clinical trials for Cervical Intraepithelial Neoplasia

Local Hyperthermia for the Treatment of Cervical Intraepithelial Neoplasias

HPV
Start date: January 28, 2018
Phase: N/A
Study type: Interventional

Human papillomavirus(HPV) infect epithelial cells and have the capacity to stimulate cell abnormal hyperplasia, especially by those high-risk HPV types. HPV vaccine primarily targeting HPV6/11/16/18 has been available and makes it possible to prevent cervical cancer. However, a large population was left unvaccinated, specifically for those aged ones. In clinic, patients harboring high-risk HPV is quite prevalent in China or other developing nations. Removing the virus and prevention of malignant transformation is required. Mild local Hyperthermia with a certain temperature range has been successfully used in the treatment of some diseases. It has been utilised in the treatment of some neoplasm, fungal and HPV infections. Investigators' study found that local hyperthermia at 44°C could cleared HPV in more than half of the patients with plantar warts. Investigators also note the fact that in patients with multiple lesions, the clearance of the target lesion is commonly followed by clearance of other distant lesions, a phenomenon suggesting that local hyperthermia could aid in establishing a specific immune response to eliminate HPV.So the purpose of the study is to evaluation local hyperthermia in the treatment of cervical intraepithelial neoplasias grade I and II after 3 months, with positive high-risk type HPVs, and patients with positive testing for high risk HPVs. Appropriate control arms were designed for different conditions.